Price Chart

Key Stats

Customize
Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
1.22% -3.75% 524.44M 87178.00
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (All)
0.00% 51.27% -- Upgrade

Basic Info

Investment Strategy
To seek long-term capital appreciation by investing primarily in equity and equity related securities of US and non-US companies principally engaged in the development, production or distribution of products or services related to scientific advances in healthcare, agriculture and environmental management. Under normal market conditions, the Trust will invest at least 65% of its total assets in securities of Life Sciences Companies. The Trust may also invest up to 40% of its net assets in securities subject to legal or contractual restrictions as to resale and up to 25% in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan.
General
Security Type Closed-End Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Health
Fund Owner Firm Name Hambrecht & Quist
Prospectus Benchmark Index
NASDAQ Biotechnology TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Daniel Omstead 19.68 yrs

Net Fund Flows Versus Category

1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
No Data Available
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: --
-4.628B Category Low
7.419B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
Date Unavailable

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of June 11, 2021. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Name
2014
2015
2016
2017
2018
2019
2020
YTD
31.16%
5.70%
-19.53%
25.44%
-14.41%
25.51%
23.80%
9.66%
4.94%
-0.87%
7.51%
22.40%
-8.71%
27.67%
15.90%
12.81%
25.60%
4.92%
-22.44%
15.99%
-13.12%
26.81%
24.92%
11.31%
47.55%
10.90%
-19.59%
37.07%
-0.30%
19.74%
12.96%
4.17%
36.34%
1.73%
-22.90%
22.28%
-0.19%
18.65%
25.66%
10.09%
--
--
--
--
--
--
--
-2.96%
As of June 11, 2021.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (6-11-21) 0.00%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 26.01
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of December 31, 2020

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of December 31, 2020

Asset Allocation

As of December 31, 2020.
Type % Net % Long % Short
Cash 2.47% Upgrade Upgrade
Stock 92.12% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 5.58% Upgrade Upgrade
Other -0.17% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
Illumina Inc 5.11% 453.17 0.55%
Amgen Inc 5.09% 242.77 -0.76%
Gilead Sciences Inc 4.75% 68.77 -0.75%
Regeneron Pharmaceuticals Inc 4.67% 525.55 -1.22%
Vertex Pharmaceuticals Inc 4.41% 193.02 -10.96%
Alexion Pharmaceuticals Inc 4.15% 181.65 -0.19%
Seagen Inc Ordinary Shares 3.51% 156.58 -1.20%
Biogen Inc 3.17% 396.64 -4.36%
Sarepta Therapeutics Inc 2.12% 86.00 -0.86%
Moderna Inc 1.99% 218.85 0.85%

Basic Info

Investment Strategy
To seek long-term capital appreciation by investing primarily in equity and equity related securities of US and non-US companies principally engaged in the development, production or distribution of products or services related to scientific advances in healthcare, agriculture and environmental management. Under normal market conditions, the Trust will invest at least 65% of its total assets in securities of Life Sciences Companies. The Trust may also invest up to 40% of its net assets in securities subject to legal or contractual restrictions as to resale and up to 25% in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan.
General
Security Type Closed-End Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Health
Fund Owner Firm Name Hambrecht & Quist
Prospectus Benchmark Index
NASDAQ Biotechnology TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Daniel Omstead 19.68 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (6-11-21) 0.00%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 26.01
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of December 31, 2020

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of December 31, 2020

Fund Details

Key Dates
Inception Date 5/8/1992
Last Annual Report Date 9/30/2020
Last Prospectus Date 11/10/1993
Attributes
Enhanced Index Fund No
Index Fund No
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan Yes
Socially Responsible Fund No